Waters Purification Solutions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Waters Purification Solutions


Waters announces the Prep 150 LC System, a new fit-for-purpose preparative chromatography system designed to isolate target compounds from crude mixtures synthesized in the laboratory or extracted from natural sources during initial purification processes.

"With this system we are responding to requests from scientists for a robust, reliable and dedicated personal chromatography system that can manage the occasional or everyday purification needs of scientists at the bench," said Wendy Harrop, Product Manager, Waters Division. "The introduction of this system demonstrates Waters commitment to serve the needs of scientists not only for analytical-scale LC but for preparative-scale purification as well."

Based on innovative high performance liquid chromatography (HPLC) hardware and software, the Waters Prep 150 LC System features ChromScope™ Software intended for scientists and technicians of all skill levels - from novice to expert - with minimal training. This dedicated HPLC system enables chemists to purify and capture quantities of specific molecular entities as part of their research into new drugs, natural products, and specialty chemicals.

The Waters Prep 150 LC System operates at flow rate ranges of up to 150 mL/min. and features options for detection, sample injection, and solvent delivery systems in order to better suit specific application needs. The Prep 150 LC is supported with a full complement of scalable Waters OBD™ preparative 10 to 50 mm (I.D.) Columns featuring 5 to 10 micron chemistries.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here